Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists

By Formea, Christine M.; Nicholson, Wayne T. et al. | American Journal of Pharmaceutical Education, February 2013 | Go to article overview

Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists


Formea, Christine M., Nicholson, Wayne T., McCullough, Kristen B., Berg, Kevin D., Berg, Melody L., Cunningham, Julie L., Merten, Julianna A., Ou, Narith N., Stollings, Joanna L., American Journal of Pharmaceutical Education


INTRODUCTION

Since the human genome project was completed in 2003, pharmacogenomics has become a rapidly expanding area of science that blends molecular pharmacology and genomics. (1) This burgeoning field investigates the important contribution of genetic inheritance in the variability of drug response. (2,3) A wide range of medication effects can be explained by genomic differences, which include but are not limited to toxic adverse effects and lack of efficacy.

The United States Food and Drug Administration (FDA) added pharmacogenomics testing requirements for several drugs, including cetuximab, dasatinib, maraviroc, and trastuzumab, and has recommended testing for abacavir, carbamazepine, mercaptopurine, and irinotecan, among others. (4) In 2007, the FDA changed warfarin labeling to include pharmacogenomics testing considerations, and in 2010, announced the addition ofa black-box warning for clopidogrel based on pharmacogenomics metabolism concerns. (5,6) The FDA also has updated the pimozide drug label to include dosing information for CYP2D6 poor metabolizers. (7) These labeling changes are among the first tangible steps toward individualized medication dosing based on a patient's genetic information.

Rapid technological advancements in molecular pharmacology and genetics are facilitating the push to translate laboratory discoveries to the patient bedside. As drug experts and point-of-care providers, pharmacists are well-positioned to lead this new era of individualized medicine. (8,9) Pharmacogenomics has moved beyond the limited confines of a laboratory environment and now represents an opportunity for clinical pharmacists to deliver enhanced patient care at the bedside and at the outpatient pharmacy window in an integrated clinical manner. (10-12)

An assessment of the pharmacogenomics educational needs of hospital and outpatient pharmacists was performed to facilitate the development of a pharmacogenomics educational program. (13) Results of the needs assessment showed that although pharmacists believed that pharmacogenomics knowledge was important to the pharmacy profession, they lacked the knowledge and self-confidence to make therapeutic recommendations based on pharmacogenomics test results. (13) Similarly, a community pharmacy survey found that pharmacists were not confident in their knowledge of genetic testing and pharmacogenomics. (14) These results suggest that pharmacists would benefit from a clinically relevant pharmacogenomics educational program. Using this information as background, the objective of this study was to measure the impact of a case-based pharmacogenomics education program for pharmacists at 1 campus of a large, academic, multicampus healthcare system.

DESIGN

A previously conducted needs-assessment survey guided the development and delivery strategies for a case-based educational program. (13) The pharmacy department at Mayo Clinic, Rochester, Minnesota, mandated the educational program for inpatient, outpatient, and administration pharmacists located on the study campus. The required educational program consisted of a 1-hour, case-based presentation focusing on fundamental principles of pharmacogenomics, including metabolic, labeling, and genomic considerations. The learning objectives for the fundamentals-of-pharmacogenomics education program included that participants be able to justify the importance of pharmacogenomics in pharmacy practice; explain pharmacogenomics concepts; evaluate pharmacokinetic alterations caused by polymorphisms; describe tests for pharmacogenomics issues; and specify FDA labeling requirements for pharmacogenomics. The concepts of pharmacogenomics were explored through patient cases based on drug-gene pairs including: abacavir (HLA-B*5701), mercaptopurine (thiopurine methyltransferase), warfarin (CYP2C9 and VKORC1), and codeine and tamoxifen (CYP2D6).

The Accreditation Council for Pharmacy Education (ACPE)-accredited educational program was presented live on 3 different occasions at various campus locations. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Development and Evaluation of a Pharmacogenomics Educational Program for Pharmacists
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.